GenSci: Two Innovations Granted IND Clearance by FDA
About GenSci
Time
2026-06-04
Readership
82
Share
Recently, GenSci145 and GenSci136 have both secured FDA clinical trial approvals, developed respectively for PIK3CA-mutated locally advanced or metastatic solid tumors and myasthenia gravis (MG).
GenSci145：Next-Generation of PI3Kα Selective Inhibitor
GenSci145 is indicated for PIK3CA-mutated locally advanced or metastatic solid tumors. PIK3CA gene mutation acts as a key driver of multiple solid tumors, occurring in 30% to 40% of breast cancer cases and conferring resistance to endocrine therapy, chemotherapy and targeted therapy in breast cancer patients[1-2]. First-generation marketed PI3Kα inhibitors are associated with adverse reactions including hyperglycemia, rash and diarrhea due to insufficient target selectivity. There is a clinical need for next-generation PI3Kα inhibitors in the PIK3CA-mutation positive patient population.
Preclinical studies demonstrate that GenSci145 exhibits high selectivity covering broader mutations, featuring improved brain penetration, and shows no traditional adverse reactions like hyperglycemia. The candidate is expected to provide new therapeutic options for the PIK3CA-mutation positive patients with brain metastasis.
GenSci136：Redefining MG Treatment by Controlling the Source of Autoantibodies
GenSci136, a BCMA fusion protein that functions as a dual antagonist of BAFF and APRIL, is indicated for myasthenia gravis.
Myasthenia gravis is a rare autoimmune disease with a global prevalence of approximately 12.4 per 100,000 people[3]. Patients often suffer fluctuating muscle weakness, ptosis, diplopia and dyspnea. Although conventional treatments can effectively manage the condition of some patients, a considerable number of patients show poor response or fail to maintain long-term treatment owing to adverse side effects.
GenSci136 blocks diverse APRIL/BAFF ligand-receptor interactions and adopts half-life extension engineering to enable potential long-term administration in humans. Preclinical studies demonstrate that GenSci136 has strong and durable efficacy against antibody-driven autoimmune diseases, offering multiple treatment options for patients.
GenSci continues its shift from a single core to a diversified therapeutic layout. Moving forward, GenSci will continue to bring more innovative therapies to patients worldwide.
Disclosure Notice：
1. Innovative drug research and development entails high risks and uncertainties.
2. This press release is provided as a medical information source for healthcare experts only and is not used for commercial purposes.
3. GenSci does not recommend the use of any unapproved drugs or indications.
Reference:
[1] MILLIS S Z, IKEDA S, REDDY S, et al. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors [J]. JAMA Oncol, 2016, 2(12): 1565-73.
[2] VASAN N, TOSKA E, SCALTRITI M. Overview of the relevance of PI3K pathway in HR-positive breast cancer [J]. Ann Oncol, 2019, 30(Suppl_10): x3-x11.
[3] Neuroimmunology Group, Neurology Branch of Chinese Medical Association. (2025). Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2025 edition). Chinese Journal of Neurology, 58(7), 721–741.
